Guerbet S. A. (GBT) - Total Liabilities
Based on the latest financial reports, Guerbet S. A. (GBT) has total liabilities worth €669.94 Million EUR (≈ $783.23 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore GBT strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Guerbet S. A. - Total Liabilities Trend (2004–2025)
This chart illustrates how Guerbet S. A.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Guerbet S. A. balance sheet assets.
Guerbet S. A. Competitors by Total Liabilities
The table below lists competitors of Guerbet S. A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cardiff Oncology Inc
NASDAQ:CRDF
|
USA | $16.50 Million |
|
Neo Technical System Co. Ltd
KQ:085910
|
Korea | ₩49.58 Billion |
|
Papoutsanis S.A
AT:PAP
|
Greece | €47.64 Million |
|
Shinsegae Food
KO:031440
|
Korea | ₩445.57 Billion |
|
Phoenix Group Holdings PLC
LSE:PHNX
|
UK | GBX331.44 Billion |
|
Cheryong Industrial Co.Ltd
KQ:147830
|
Korea | ₩11.65 Billion |
|
Getty Images Holdings Inc.
NYSE:GETY
|
USA | $2.63 Billion |
|
Cemacon Zalau
RO:CEON
|
Romania | RON176.26 Million |
Liability Composition Analysis (2004–2025)
This chart breaks down Guerbet S. A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Guerbet S. A. (GBT) net asset quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.49 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.51 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.72 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Guerbet S. A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Guerbet S. A. (2004–2025)
The table below shows the annual total liabilities of Guerbet S. A. from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €669.94 Million ≈ $783.23 Million |
+3.76% |
| 2024-12-31 | €645.68 Million ≈ $754.87 Million |
-0.20% |
| 2023-12-31 | €646.97 Million ≈ $756.38 Million |
+15.52% |
| 2022-12-31 | €560.07 Million ≈ $654.78 Million |
-5.99% |
| 2021-12-31 | €595.74 Million ≈ $696.48 Million |
+3.08% |
| 2020-12-31 | €577.95 Million ≈ $675.69 Million |
-6.73% |
| 2019-12-31 | €619.68 Million ≈ $724.47 Million |
-13.22% |
| 2018-12-31 | €714.05 Million ≈ $834.80 Million |
+16.78% |
| 2017-12-31 | €611.45 Million ≈ $714.85 Million |
-14.28% |
| 2016-12-31 | €713.35 Million ≈ $833.98 Million |
+15.05% |
| 2015-12-31 | €620.06 Million ≈ $724.91 Million |
+186.36% |
| 2014-12-31 | €216.53 Million ≈ $253.15 Million |
-2.15% |
| 2013-12-31 | €221.29 Million ≈ $258.72 Million |
-5.73% |
| 2012-12-31 | €234.76 Million ≈ $274.46 Million |
-0.07% |
| 2011-12-31 | €234.92 Million ≈ $274.65 Million |
+11.08% |
| 2010-12-31 | €211.49 Million ≈ $247.26 Million |
+11.89% |
| 2009-12-31 | €189.01 Million ≈ $220.98 Million |
-4.17% |
| 2008-12-31 | €197.23 Million ≈ $230.58 Million |
+5.89% |
| 2007-12-31 | €186.26 Million ≈ $217.75 Million |
+6.81% |
| 2006-12-31 | €174.37 Million ≈ $203.86 Million |
+12.75% |
| 2005-12-31 | €154.65 Million ≈ $180.81 Million |
+14.17% |
| 2004-12-31 | €135.46 Million ≈ $158.37 Million |
-- |
About Guerbet S. A.
Guerbet SA provides a range of contrast media, medical devices, and digital and AI solutions for diagnostic and interventional imaging worldwide. It offers DOTAREM, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced MRI examinations; Elucirem, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced resonance imaging; UNIK, a diagnostic imaging interconne… Read more